Max Estates' record is clean on audit opinions, but the financials tell a different story: cumulative operating cash flow is negative ₹536 crore over four years against a reported profit, net debt to EBITDA exceeds 75 times, and the headline net-debt figure excludes ₹524 crore of high-coupon debentures owed to a co-investor.
Key findings
- Operating cash flows are deeply negative and disconnected from reported profits
Major- Consolidated cash flow from operations was ₹-616 crore in FY26, bringing the four-year cumulative CFO to ₹-536 crore against cumulative EBITDA of ₹148 crore. The Group capitalised ₹121.48 crore of borrowing costs and ₹4.21 crore of employee stock option expense into project assets in FY26, keeping those costs off the profit-and-loss statement. Net debt to EBITDA stood at 75.7 times and interest cover fell to 1.36 times in FY26. - Headline net-debt excludes ₹524 crore of high-coupon CCDs owed to New York Life
Major- Management's reported net-debt of ₹97 crore as of March 31, 2026 explicitly excludes ₹524 crore of Compulsorily Convertible Debentures and accrued interest owed to New York Life. These CCDs carry a 20% per annum compounded coupon and are mandatorily convertible into equity. Consolidated borrowings stood at ₹2,412 crore, with ₹2,196 crore residing in subsidiaries secured by parent guarantees and pledged subsidiary shares. - Reported profit depends heavily on non-operating gains and policy choices that defer costs
Major- The FY2022-23 merger was accounted from an appointed date rather than the combination date, and comparatives were not restated, a departure from Ind AS 103 that the auditor flagged in an Emphasis of Matter paragraph. In FY2024-25 standalone, the company recognised a gain of ₹218.89 crore on direct sale of shares to NYL and a gain of ₹56.21 crore on sale of Max House A to a subsidiary, both booked under other income. QIP expenses of ₹19.77 crore were adjusted against Securities Premium, bypassing the profit and loss statement. - Revenue recognition is heavily back-loaded by project-completion milestones
Minor- Management reports cumulative unrecognised revenue from launched projects of ₹16,310 crore as of the FY26 AGM notice, against consolidated revenue from operations of just ₹199.45 crore in FY26. Standalone revenue from operations was ₹55.47 crore in FY26. The company expects to receive only an incremental ₹550-600 crore in cash from the Max One inherited sales against the ₹1,221 crore of revenue recognised from those sales. - Promoter family holds board control and extracts fixed ₹3 crore annual compensation for the Non-Executive Chairman
Minor- Mr. Analjit Singh received gross compensation of ₹3 crore per annum in each of FY2024, FY2025, and FY2026, approved by shareholders as exceeding 50% of total remuneration payable to all Non-Executive Directors. Public institutional shareholders voted 88.86% against the resolution approving his ₹3 crore compensation for FY2027 at the postal ballot concluded March 23, 2026. Mr. Sahil Vachani, his son-in-law, received ₹6.87 crore during FY2026 under a five-year remuneration ceiling with a minimum-remuneration guarantee if the company has inadequate profits. - Clean audit opinions across all years, with an audit-trail gap from privileged database access
Minor- The statutory auditor issued an unqualified opinion on standalone and consolidated financial statements for each year from FY2023 through FY2026. However, the auditor reported that the audit trail feature was not enabled for certain changes made directly to the database using privileged access rights in FY2024, FY2025, and FY2026. The auditor's consolidated report relied on other auditors for subsidiaries whose total assets grew to ₹10,234.24 crore in FY2026. - The group has expanded through a layered web of 14 SPVs, with New York Life holding 49% across the commercial portfolio
Minor- As of March 31, 2026, Max Estates Ltd had 14 SPVs, up from 8 a year earlier. New York Life Insurance Company holds a 49% stake across the entire commercial real estate portfolio. As of March 31, 2023, all six subsidiaries then disclosed reported net worth of zero, each with total assets exactly equal to total liabilities.
What to watch
- FY27 construction spend. Planned construction spend of over ₹1,500 crore for FY27, disclosed in the AGM notice dated 28 July 2026, will test whether capitalisation rates and debt service capacity can be sustained.
- New York Life CCD conversion. Series B and D CCDs are convertible after six years from March 18, 2020 and November 7, 2022 respectively, or upon full exit by New York Life.
- Antara Senior Living RPT approval. Shareholder approval sought for material related-party transactions with Antara Senior Living Limited for FY27, with fees up to ₹40 crore per subsidiary, outcome pending as of the FY2026 reporting period.
- Pharmax Corporation GST notice. Resolution of the show cause notice dated July 27, 2026, proposing a demand of ₹5.90 crore for FY2023.
- Audit-trail exception. The FY2027 audit report for the period ending March 31, 2027, for any modification to the audit-trail exception regarding privileged database access.
Bottom line: This is a disclosed and audited record built on a real-estate development model where cash outflows precede revenue by years, and costs are systematically capitalised into project assets. The risk sits in three places: the gap between reported profit and operating cash flow, the exclusion of ₹524 crore of high-coupon CCDs from the headline net-debt figure, and the layered co-investment structure where parent guarantees sit beneath a thin standalone balance sheet. Watch the FY27 construction spend against debt service capacity, and read the cash-flow statement before the income statement.